Daily ischemic preconditioning provides sustained protection from ischemia-reperfusion induced endothelial dysfunction: A human study

Journal of the American Heart Association

Volumn 2, Issue 1, 2013, Pages

  Luca, Mary Clare ^a,b   Liuni, Andrew ^a,b   McLaughlin, Kelsey ^a,b   Gori, Tommaso ^c   Parker, John D ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Cyclooxygenase 2; Endothelium; Ischemia; Ischemic preconditioning; Reperfusion

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; PLACEBO; CYCLOOXYGENASE 2 INHIBITOR; PTGS2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADULT; ARTICLE; BLOOD VESSEL FUNCTION; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; FLOW MEDIATED DILATION; FOREARM; HUMAN; ISCHEMIC PRECONDITIONING; MALE; PRIORITY JOURNAL; PROTECTION; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TREATMENT DURATION; ANALYSIS OF VARIANCE; CANADA; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ENZYMOLOGY; HYPEREMIA; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; TIME; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASODILATATION;

ADULT; ANALYSIS OF VARIANCE; CROSS-OVER STUDIES; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; ENDOTHELIUM, VASCULAR; FOREARM; HUMANS; HYPEREMIA; ISCHEMIC PRECONDITIONING; MALE; ONTARIO; PYRAZOLES; REPERFUSION INJURY; SULFONAMIDES; TIME FACTORS; VASODILATION; YOUNG ADULT;

EID: 84884191941     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.112.000075     Document Type: Article

References (35)

1. Ovize M, Baxter GF, Di Lisa F, Ferdinandy P, Garcia-Dorado D, Hausenloy DJ, Heusch G, Vinten-Johansen J, Yellon DM, Schulz R; Working Group of Cellular Biology of Heart of European Society of Cardiology. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2010;87:406-423.
2. Vinten-Johansen J, Zhao ZQ, Nakamura M, Jordan JE, Ronson RS, Thourani VH, Guyton RA. Nitric oxide and the vascular endothelium in myocardial ischemiareperfusion injury. Ann N Y Acad Sci. 1999;874:354-370.
3. Laude K, Beauchamp P, Thuillez C, Richard V. Endothelial protective effects of preconditioning. Cardiovasc Res. 2002;55:466-473.
4. Kharbanda RK, Peters M, Walton B, Kattenhorn M, Mullen M, Klein N, Vallance P, Deanfield J, MacAllister R. Ischemic preconditioning prevents endothelial injury and systemic neutrophil activation during ischemia-reperfusion in humans in vivo. Circulation. 2001;103:1624-1630.
5. Ehring T, Krajcar M, Baumgart D, Kompa S, Hummelgen M, Heusch G. Cholinergic and alpha-adrenergic coronary vasomotion [corrected] with increasing ischemia-reperfusion injury. Am J Physiol. 1995;268:H886-H894.
6. Scarabelli T, Stephanou A, Rayment N, Pasini E, Comini L, Curello S, Ferrari R, Knight R, Latchman D. Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia/reperfusion injury. Circulation. 2001;104:253-256.
7. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124-1136.
8. Liem DA, Honda HM, Zhang J, Woo D, Ping P. Past and present course of cardioprotection against ischemia-reperfusion injury. J Appl Physiol. 2007; 103:2129-2136.
9. Leesar MA, Stoddard MF, Dawn B, Jasti VG, Masden R, Bolli R. Delayed preconditioning-mimetic action of nitroglycerin in patients undergoing coronary angioplasty. Circulation. 2001;103:2935-2941.
10. Walsh SR, Tang TY, Kullar P, Jenkins DP, Dutka DP, Gaunt ME. Ischaemic preconditioning during cardiac surgery: systematic review and meta-analysis of perioperative outcomes in randomised clinical trials. Eur J Cardiothorac Surg. 2008;34:985-994.
11. Botker HE, Kharbanda R, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ, Munk K, Andersen NH, Hansen TM, Trautner S, Lassen JF, Christiansen EH, Krusell LR, Kristensen SD, Thuesen L, Nielsen SS, Rehling M, Sorensen HT, Redington AN, Nielsen TT. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet. 2010;375:727-734.
12. Gori T, Sicuro S, Dragoni S, Donati G, Forconi S, Parker JD. Sildenafil prevents endothelial dysfunction induced by ischemia and reperfusion via opening of adenosine triphosphate-sensitive potassium channels: a human in vivo study. Circulation. 2005;111:742-746.
13. Gori T, Di Stolfo G, Sicuro S, Dragoni S, Lisi M, Forconi S, Parker JD. Nitroglycerin protects the endothelium from ischaemia and reperfusion: human mechanistic insight. Br J Clin Pharmacol. 2007;64:145-150.
14. Dragoni S, Gori T, Di SG, Sicuro S, Forconi S, Parker JD. Folic acid does not limit endothelial dysfunction induced by ischemia and reperfusion: a human study. J Cardiovasc Pharmacol. 2005;46:494-497.
15. Gori T, Dragoni S, Lisi M, Di Stolfo G, Sonnati S, Fineschi M, Parker JD. Conduit artery constriction mediated by low flow a novel noninvasive method for the assessment of vascular function. J Am Coll Cardiol. 2008;51:1953-1958.
16. Yellon DM, Downey JM. Preconditioning the myocardium: from cellular physiology to clinical cardiology. Physiol Rev. 2003;83:1113-1151. 17. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007; 357:1121-1135.
17. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med. 2007; 357:1121-1135.
18. Lambiase PD, Edwards RJ, Cusack MR, Bucknall CA, Redwood SR, Marber MS. Exercise-induced ischemia initiates the second window of protection in humans independent of collateral recruitment. J Am Coll Cardiol. 2003; 41:1174-1182.
19. Dana A, Baxter GF, Walker JM, Yellon DM. Prolonging the delayed phase of myocardial protection: repetitive adenosine a1 receptor activation maintains rabbit myocardium in a preconditioned state. J Am Coll Cardiol. 1998;31:1142-1149.
20. Kuzume K, Wolff RA, Amakawa K, Van Winkle DM. Sustained exogenous administration of Met5-enkephalin protects against infarction in vivo. Am J Physiol Heart Circ Physiol. 2003;285:H2463-H2470.
21. Peart JN, Gross GJ. Morphine-tolerant mice exhibit a profound and persistent cardioprotective phenotype. Circulation. 2004;109:1219-1222.
22. Mensah K, Mocanu MM, Yellon DM. Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? J Am Coll Cardiol. 2005; 45:1287-1291.
23. Gori T, Dragoni S, Di Stolfo G, Sicuro S, Liuni A, Luca MC, Thomas G, Oelze M, Daiber A, Parker JD. Tolerance to nitroglycerin-induced preconditioning of the endothelium: a human in vivo study. Am J Physiol Heart Circ Physiol. 2010;298: H340-H345.
24. Briguori C, Colombo A, Airoldi F, Violante A, Focaccio A, Balestrieri P, Paolo EP, Golia B, Lepore S, Riviezzo G, Scarpato P, Librera M, Bonizzoni E, Ricciardelli B. Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. Eur Heart J. 2004;25:1822-1828.
25. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di SG. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Circulation. 2004;110:674-678.
26. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol. 2007;49:1272-1278.
27. Mannacio VA, Iorio D, De AV, Di LF, Musumeci F. Effect of rosuvastatin pretreatment on myocardial damage after coronary surgery: a randomized trial. J Thorac Cardiovasc Surg. 2008;136:1541-1548.
28. Liuni A, Luca MC, Gori T, Parker JD. Loss of the preconditioning effect of rosuvastatin during sustained therapy: a human in vivo study. Am J Physiol Heart Circ Physiol. 2012;302:H153-H158.
29. Shen Y-T, Depre C, Yan L, Park JY, Tian B, Jain K, Chen L, Zhang Y, Kudej RK, Zhao X, Sadoshima J, Vatner DE, Vatner SF. Repetitive ischemia by coronary stenosis induces a novel window of ischemic preconditioning. Circulation. 2008;118:1961-1969.
30. Depre C, Park JY, Shen YT, Zhao X, Qiu H, Yan L, Tian B, Vatner SF, Vatner DE. Molecular mechanisms mediating preconditioning following chronic ischemia differ from those in classical second window. Am J Physiol Heart Circ Physiol. 2010;299:H752-H762.
31. Cohen MV, Yang XM, Downey JM. Conscious rabbits become tolerant to multiple episodes of ischemic preconditioning. Circ Res. 1994;74:998-1004.
32. Papadopoulos CE, Karvounis HI, Parharidis GE, Louridas GE. Multiple episodes of ischemic preconditioning are not associated with loss of benefit: preliminary clinical experience. Can J Cardiol. 2005;21:1291-1295.
33. Bolli R. Preconditioning: a paradigm shift in the biology of myocardial ischemia. Am J Physiol Heart Circ Physiol. 2007;292:H19-H27.
34. Bolli R, Shinmura K, Tang X-L, Kodani E, Xuan Y-T, Guo Y, Dawn B. Discovery of a new function of cyclooxygenase (Cox)-2: Cox-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res. 2002;55:506-519.
35. Liuni A, Luca MC, Gori T, Parker JD. Rosuvastatin prevents conduit artery endothelial dysfunction induced by ischemia and reperfusion by a cyclooxygenase- 2-dependent mechanism. J Am Coll Cardiol. 2010;55:1002-1006.